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Background: Whether diagnostic route (e.g. emergency presentation) is associated with cancer care experience
independently of tumour stage is unknown.
Methods: We analysed data on 18 590 patients with breast, prostate, colon, lung, and rectal cancers who re-
sponded to the 2014 English Cancer Patient Experience Survey, linked to cancer registration data on diagnostic
route and tumour stage at diagnosis. We estimated odds ratios (OR) of reporting a negative experience of overall
cancer care by tumour stage and diagnostic route (crude and adjusted for patient characteristic and cancer site
variables) and examined their interactions with cancer site.
Results: After adjustment, the likelihood of reporting a negative experience was highest for emergency pre-
senters and lowest for screening-detected patients with breast, colon, and rectal cancers (OR versus two-week-
wait 1.51, 95% confidence interval [CI] 1.24–1.83; 0.88, 95% CI 0.75–1.03, respectively). Patients with the most
advanced stage were more likely to report a negative experience (OR stage IV versus I 1.37, 95% CI 1.15–1.62)
with little confounding between stage and route, and no evidence for cancer-stage or cancer-route interactions.
Conclusions: Though the extent of disease is strongly associated with ratings of overall cancer care, diagnostic
route (particularly emergency presentation or screening detection) exerts important independent effects.
1. Introduction
A positive experience of cancer care is increasingly understood to
represent a key aspect of high quality cancer services. [1,2] In several
countries, this realisation has led to initiatives supporting the mea-
surement of the experience of cancer patients through patient surveys.
[3–8] While those surveys chiefly focus on the public reporting of
hospital scores of patients’ satisfaction with cancer care, understanding
person-level variation is also important.
Women, younger and very old, and ethnic minority patients report
worse cancer care experiences. [9,10] Additionally, certain cancer sites,
particularly those with generally poor survival such as lung cancer, are
associated with worse than average experiences (and vice versa for
cancer sites with good prognosis, such as breast cancer) [9]. In spite of
evidence on socio-demographic and cancer site variation in patient
experience, there is little appreciation of how disease factors (including
tumour stage at diagnosis) are associated with the experience of cancer
care. Such influences are indeed plausible, as demonstrated by previous
research showing that patients with different types of cancer reported
variable experiences even when treated by the same specialty. [11]
Diagnostic route [12,13], denoting whether the cancer was diagnosed
thorough screening detection, or in an elective or emergency care
context, has prognostic implications and may also be important for
patient experience. Previously examined associations between diag-
nostic route and cancer care experience were confined to a single
cancer (colorectal) and did not account for potential confounding of the
examined associations by tumour stage. [14]
We therefore aimed to examine whether in patients with common
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cancers diagnostic route and tumour stage at diagnosis are in-
dependently associated with differential evaluation of cancer care ex-
perience.
2. Methods
2.1. Data source
We analysed anonymous data from responders to the 2014 English
Cancer Patient Experience Survey (CPES),[3] a postal survey of patients
aged 16 years and older who were treated for cancer in English National
Health Service (NHS) hospitals during the period September–November
2013. The survey was commissioned by NHS England and provided by
Quality Health. Following vital status checks, patients were sent a
survey questionnaire by post, with up to two reminders for non-re-
sponders. Of the 109 760 surveyed patients, 70 141 responded to the
survey (response rate = 64%).
2.2. Variables
Outcome. We examined responses to the survey question 70:
‘Overall, how would you rate your care?’, with five possible informative
response categories of 'Excellent / Very good / Good / Fair / Poor'.
Responses were dichotomised into two broad categories defined as
‘positive’ Excellent - Very good) and ‘negative’ (all other response op-
tions) ratings, consistent with how this item is reported publicly. [3]
Main exposures. The exposures of primary interest were tumour
stage at diagnosis and diagnostic route. Information on these two
variables was provided by linkage of the 2014 CPES responders’ sample
to the cancer registration data, carried out by the Public Health England
National Cancer Registration and Analysis Services (PHE NCRAS).
[15–17] Data were linked deterministically on the basis of matching
NHS patient numbers and relevant International Classification of Dis-
ease (ICD)-10 diagnosis codes [18], taking into account relevant diag-
nosis time windows. [16]
Diagnostic route refers to care pathways leading to the diagnosis of
cancer. It is derived algorithmically (by PHE NCRAS) linking together
cancer registration, Hospital Episode Statistics, screening, and Cancer
Waiting Times data. [12] We used a five-category definition of diag-
nostic route, comprising the following [12,14].
• Emergency presentation: cancer diagnosis soon after any of emer-
gency hospital admission, attendance at the Accident and
Emergency department, emergency GP referral or emergency be-
tween-hospital transfer;• Urgent primary to secondary care referral for suspected cancer (also
known as ‘two-week-wait’ referral): patients are to be assessed by
specialist hospital services within two weeks;• Elective primary to secondary care referral: primary care referral other
than through the two-week-wait route where patients attend routine
(non-urgent) out-patient appointments;• Screening detection: breast, or colon/rectal cancer diagnosis fol-
lowing participation in NHS screening programmes.• Other routes: not described above.
Tumour stage at diagnosis is based on the relevant field of the
English cancer registration system and is assigned by registrars based
on information on clinical, pathology, and imaging records. For the
analysis, tumour stage was defined as stages I (least advanced) to IV
(most advanced)13. A small number of stage-0 patients were also
treated as having stage-I tumours.
Other covariates. We also considered the responders’ age group
(<55, 55–64, 65–74, 75+ years old), sex, and deprivation status
(quintiles 1 to 5, from least to most deprived), based on cancer regis-
tration data. For deprivation status, the population-weighted quintile of
the income domain from the Indices of Multiple Deprivation (IMD)
2015 [19] was derived by assigning each patient to the deprivation
category of their Lower Super Output Areas using the postcode of re-
sidence at the time of diagnosis. Patients’ cancer diagnoses were re-
corded using the ICD-10 diagnosis codes [18] based on cancer regis-
tration data.
2.3. Sample derivation
We a priori restricted our analyses to survey responders who in-
dicated that they had been treated for cancer in the last year (using
responses to question 76: ‘How long is it since you were first treated for
this cancer?’), and patients with the five most common sites (breast,
prostate, lung, colon, and rectal cancer). In the context of relatively
high data completeness, we excluded from subsequent analyses re-
sponders with missing information on the outcome (response to ques-
tion 70), tumour stage, diagnostic route, and patient characteristic
variables.
2.4. Statistical analysis
We first calculated the crude proportions of reporting a negative
experience of overall cancer care by diagnostic route and tumour stage.
Subsequently, we used logistic regression models to examine the asso-
ciations of overall cancer care rating with diagnostic route and tumour
stage. We obtained (i) the unadjusted odds ratios (OR) of reporting a
negative experience for diagnostic route or tumour stage; (ii) the ad-
justed ORs for either diagnostic route or tumour stage (in different
models), conditional on patient characteristic and cancer site variables;
and (iii) the adjusted ORs for both diagnostic route and tumour stage in
the same model, conditional on patient characteristic and cancer site
variables. In the final multivariable logistic regression model with both
diagnostic route and tumour stage, we further examined pairwise in-
teractions of each of these two variables with cancer site. All analyses
were conducted in Stata v15.2 [20].
3. Results
In total, there were 21 934 patients with a diagnosis of one of the
five studied cancers (breast, prostate, lung, colon, rectal) who had been
treated in the last year. After exclusions due to missing data, the ana-
lysis sample comprised 18 590 responders (Fig. 1). Across cancer sites,
Fig. 1. Analysis sample derivation. CPES: Cancer Patient Experience Survey.
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there were associations between tumour stage and diagnostic route,
with stage IV being generally more frequent among emergency pre-
senters and stage I among screening-detected patients (with breast,
colon, and rectal cancer) (Appendix 1). There was large variation in
both tumour stage and diagnostic route by patient characteristic vari-
ables and cancer site (Appendix 2).
The percentage of patients reporting a negative experience of
overall cancer care was 10% (Table 1). Table 1 and Fig. 2 present the
frequencies and percentages, as well as crude and adjusted odds ratios
of a negative rating of overall cancer care by tumour stage and diag-
nostic route, as well as other patient characteristic and cancer site
variables.
Overall, the younger and the very old patients, those living in more
deprived areas, and those with prostate cancer were more likely to
report a negative experience of cancer care (Table 1).
In fully adjusted analysis (including patient characteristic, cancer site,
tumour stage, and diagnostic route variables) younger patients (OR <55
vs 65–74 years old 1.58, 95% confidence interval [CI] 1.37–1.83);
women (OR female vs male 1.51, 95% CI 1.29–1.76); and those living in
more deprived areas (OR deprivation quintile 5 vs 1 1.50, 95% CI
1.28–1.77) had a higher likelihood of reporting a negative experience of
overall care. There was some variation by cancer site, with breast cancer
having the lowest and prostate cancer the highest likelihood of reporting
a negative rating of overall care (Table 1, Fig. 2). Comparing the results
from unadjusted and adjusted analyses we observed a similar overall
pattern of variation, though this comparison indicated a substantial
amount of confounding between sex and cancer site.
In the same adjusted model, tumour stage and diagnostic route were
(independently of each other) associated with satisfaction ratings of
overall cancer care. Patients diagnosed with stage IV tumours were
most likely to report an overall negative experience of their care (OR
stage IV vs stage I 1.37, 95% CI 1.15–1.62), as were those diagnosed
through an emergency presentation (OR emergency vs two-week-wait
referral 1.51, 95% CI 1.24–1.83). Patients diagnosed through an elec-
tive (i.e. not two-week-wait) referral were also more likely to report a
negative experience than those diagnosed through screening or two-
week-wait referral (OR elective vs two-week-wait referral 1.24, 95% CI
1.09–1.43). Screening detected patients (with breast, colon, and rectal
cancers) had a lower risk of reporting a negative experience of their
care than those diagnosed via other routes (OR screening vs two-week-
wait 0.88, 95% CI 0.75–1.03). Comparing the fully adjusted model to
the one which excludes diagnostic route shows that there was only
minor attenuation of the effect associated with tumour stage at diag-
nosis when adjusting for diagnostic route (e.g. OR for stage IV vs I de-
creased from 1.44 to 1.37). Similarly, there was only a small attenua-
tion in the effect of diagnostic route when adjusting for stage (e.g. OR
for emergency presentation vs two-week-wait referral decreased from
1.60 to 1.51).
In additional analyses, there was no evidence for pairwise interac-
tions between cancer site and either tumour stage (p-value = 0.117), or
diagnostic route (p-value = 0.628) (Appendix 3). In other words, there
was no evidence that the associations between ratings of overall cancer
care and either tumour stage or diagnostic route varied between pa-
tients with the studied cancers.
4. Discussion
4.1. Summary of findings
Among patients with breast, prostate, lung, colon, and rectal can-
cers, emergency presentation, elective referral route and stage-IV tu-
mours at diagnosis were associated with a higher likelihood of re-
porting a negative experience of overall care, after adjusting for other
patient characteristic and cancer site variables. Although there was
evidence that some of the effect of stage at diagnosis operated through
diagnostic route and vice-versa, the magnitude of this mediation was
small and the two variables are associated with ratings of overall care
independently of each other.
4.2. Strengths and limitations
Our analyses were based on data from a large nationwide sample of
cancer patients with high response rate – representing the largest
available collection of patient experience data in cancer patients.
Information on tumour stage and diagnostic route was provided by
linkage to population-based datasets, which enabled us to examine
their associations with overall cancer care experience ratings. We were
able to adjust our principal findings (with regard to associations with
tumour stage and diagnostic route) for a range of patient factors, in-
cluding age group, sex, deprivation, and cancer site, which are known
to be associated with patient experience. [9,21,22] The overall com-
pleteness of the outcome and exposure variables in our analysis sample
was high.
The survey (CPES) responders were patients recently treated for
cancer in NHS hospitals, a patient population with certain composi-
tional differences compared with incident or prevalent cancer cases.
[23] These compositional differences arise from differences in survival
in patient groups with different prognosis, both regarding patients with
different cancers (e.g. resulting in a relative ‘deficit’ of responders with
lung or pancreatic cancers, compared with a relative ‘excess’ of re-
sponders with breast cancer or melanoma) or between patient sub-
groups with the same cancer. Further, differential non-response (with
men, younger and very old patients, more deprived, and ethnic min-
ority patients being less likely to respond), and differential treatment
patterns and duration also result in compositional differences between
patient survey responders and other populations of cancer patients
[23]. Relatedly, as patients diagnosed at advanced stages or through an
emergency presentation had a higher risk of early mortality [24], they
were under-represented in patient surveys. While these considerations
may suggest that our analyses have underestimated the overall pre-
valence of negative ratings of care, such differences are unlikely to have
substantially biased the estimates of associations. Additionally, the fact
that CPES responders consisted of a special population (cancer survi-
vors with recent hospital treatment) needs to be borne in mind when
interpreting the findings.
Given the public reporting conventions for this survey, we dichot-
omised the outcome (i.e. overall satisfaction with care) in our analysis.
Future work may explore alternative parameterisations for analysing
this item.
4.3. Comparisons with existing evidence
We were not aware of previous studies that characterise associations
between reported patient experience of cancer care and both tumour
stage at diagnosis and diagnostic route considered together. With re-
gard to examining associations between cancer patient experience and
tumour stage, a recent Dutch study assessed the level of satisfaction
with hospital care among patients with advanced cancer and found no
evidence for an association between a surrogate of stage (estimated life
expectancy in months) and general satisfaction with care. [10] Simi-
larly, a US study on ratings of quality of cancer care among a sample of
lung and colorectal cancer patients indicated no association between
tumour stage and overall ratings of cancer care in the adjusted analysis.
[26] It is worth noting that the first of these studies had a very small
sample size (N=105) and that both studies adjusted for health status
which is likely to mediate the effect of tumour stage at diagnosis.
With regard to examining associations between cancer patient ex-
perience and diagnostic route, a previous study [14] examined the
impact of diagnostic route (without adjustment for stage at diagnosis)
on reported experience of key aspects of cancer care (not including
satisfaction with overall cancer care) among colorectal cancer patients
who responded to the 2010 CPES; screen-detected patients were found
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to be associated with the best and emergency presenters the worst ex-
perience of cancer care. In addition, two recent Danish studies reported
that cancer patients managed through ‘fast-track’ referrals (similar to
the two-week-wait route) were less likely to be dissatisfied with the
length of waiting times and more likely to be satisfied with their sub-
sequent cancer care, compared with those referred electively. [27,28]
Our study cannot explain the reasons for the observed variation in care
satisfaction by diagnostic route. The fact that emergency presenters
were found to be the least satisfied with their care may reflect the ne-
gative psychological impact of being diagnosed in an emergency con-
text. Similarly, electively referred patients may rate their care more
negatively if they feel that their diagnosis could have been more timely
had they been ‘fast-tracked’ through a two-week-wait referral, as per-
ceived diagnostic delay is associated with distress. [29] These are
plausible and intuitive hypotheses which should be examined empiri-
cally by further research. These previous studies however were not able
to adjust for the likely influence of stage at diagnosis on the diagnostic
pathways. In contrast, in our study we were able to examine the in-
fluence of both diagnostic route and stage at diagnosis, with the ad-
justed analysis indicating that both could be influencing care experi-
ence independently of each other.
4.4. Implications
The finding that emergency presenters and patients with the most
advanced tumour stage were more likely to report a negative experi-
ence of overall cancer care highlights the need for service improvement
targeting these groups of patients. There may be opportunities to im-
prove the availability of services (e.g. in the context of emergency
presentations) or the management of patients with advanced tumour
stages, though how this can be achieved should be addressed in future
research. Continued efforts to improve timely diagnosis of cancer and to
reduce the number of emergency presenters will also likely lead to a
reduction in the number of patients who are not satisfied with the
quality of their care.
The results also suggest that after adjusting for tumour stage and
diagnostic route, sociodemographic inequalities (by age, sex, and social
deprivation) prevailed. Therefore, disease severity does not appear to
fully explain these disparities. Whether these disparities reflected dif-
ferential norms in expectations of care quality or actually worse care
cannot be answered by our findings. Future empirical research, such as
using standardised encounters (e.g. ‘vignettes’) may be helpful. [30]
When cancer patient survey data are used for epidemiological re-
search, potential compositional differences between the analysis sample
(which represents recently treated cancer survivors) and other popu-
lations of prior interest (e.g. incident or prevalent cases) might limit the
external validity of findings. Therefore, in addition to the variation in
reported experience by patient characteristic and cancer site variables,
[9] associations between diagnostic route, tumour stage at diagnosis,
and reported experience need to be considered when applying methods
for dealing with sample distortions, such as the inclusion of these
variables in deriving post-stratification weights. [25]
4.5. Conclusions
In conclusion, we report variation in experience of overall care
among cancer patients with different tumour stages at diagnosis, di-
agnostic routes, and other characteristics. These associations need to be
borne in mind when using patient experience survey data for epide-
miological research. A reduction in the proportion of patients who are
diagnosed with cancer as an emergency, greater availability and uptake
of screening interventions, and reduction in the incidence of late-stage
diseases may contribute to improvements in care experience. The
findings could guide improvement efforts in the care of patients diag-
nosed via emergency presentation and those with advanced-stage dis-
ease, who are also higher-risk groups of reporting poorer experience of
cancer care.
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Appendix
Appendix 1 Frequency of tumour stage at diagnosis and diagnostic route by the five most common cancers, N= 18 590
Cancer site Tumour stage at diagnosis Two-week-wait Emergency presentation Elective referral Screening detection Other routes Total pa
Breast 1 1 316 9 168 1 808 66 3 367 <0.001
Row % 39 0 5 54 2 100
Col % 29 11 40 61 66 41
2 2 374 30 180 954 18 3 556
Row % 67 1 5 27 1 100
Col % 52 35 43 32 18 44
3 718 19 46 194 11 988
Row % 73 2 5 20 1 100
Col % 16 22 11 7 11 12
4 141 27 21 22 5 216
Row % 65 13 10 10 2 100
Col % 3 32 5 1 5 3
Total 4 549 85 415 2 978 100 8 127
Row % 56 1 5 37 1 100
Col % 100 100 100 100 100 100
Prostate 1 345 27 460 108 940 <0.001
Row % 37 3 49 11 100
Col % 25 26 35 45 31
2 377 12 437 54 880
Row % 43 1 50 6 100
Col % 28 12 33 22 29
3 397 9 326 47 779
Row % 51 1 42 6 100
Col % 29 9 25 19 26
4 236 54 94 33 417
Row % 57 13 23 8 100
Col % 17 53 7 14 14
Total 1 355 102 1 317 242 3 016
Row % 45 3 44 8 100
Col % 100 100 100 100 100
Colon 1 111 9 81 118 33 352 <0.001
Row % 32 3 23 34 9 100
Col % 10 2 12 24 10 11
2 392 145 242 149 118 1 046
Row % 37 14 23 14 11 100
Col % 35 26 35 30 37 33
3 393 226 239 195 107 1 160
Row % 34 19 21 17 9 100
Col % 35 40 34 39 33 36
4 216 182 135 38 62 633
Row % 34 29 21 6 10 100
Col % 19 32 19 8 19 20
Total 1 112 562 697 500 320 3 191
Row % 35 18 22 16 10 100
Col % 100 100 100 100 100 100
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Lung 1 199 45 139 99 482 <0.001
Row % 41 9 29 21 100
Col % 17 15 25 26 20
2 184 36 94 57 371
Row % 50 10 25 15 100
Col % 16 12 17 15 15
3 379 76 149 115 719
Row % 53 11 21 16 100
Col % 32 25 27 30 30
4 412 149 178 117 856
Row % 48 17 21 14 100
Col % 35 49 32 30 35
Total 1174 306 560 388 2 428
Row % 48 13 23 16 100
Col % 100 100 100 100 100
Rectal 1 127 9 78 82 38 334 <0.001
Row % 38 3 23 25 11 100
Col % 14 10 18 29 26 18
2 169 23 76 63 27 358
Row % 47 6 21 18 8 100
Col % 19 25 18 22 18 20
3 418 32 200 119 60 829
Row % 50 4 24 14 7 100
Col % 47 35 47 41 41 45
4 167 27 69 23 21 307
Row % 54 9 22 7 7 100
Col % 19 30 16 8 14 17
Total 881 91 423 287 146 1 828
Row % 48 5 23 16 8 100
Col % 100 100 100 100 100 100
ap-values from Chi-squared tests of associations.
Appendix 2 Associations between key exposures (tumour stage at diagnosis, diagnostic route) and patient characteristic and cancer site variables, N=18 590
Variable Tumour stage at diagnosis Diagnostic route
I II III IV pa Two-week-
wait
Emergency presenta-
tion
Elective re-
ferral
Screening detec-
tion
Other
routes
Total pa
Age group
<55 1 221 1 743 774 326 <0.001 2 465 173 502 753 171 4 064 <0.001
22 28 17 13 27 15 15 20 14 22
55-64 1 501 1 505 1 173 586 1 984 261 823 1 415 282 4 765
27 24 26 24 22 23 24 38 24 26
65-74 1 880 1 799 1 672 927 2 635 399 1 325 1 485 434 6 278
34 29 37 38 29 35 39 39 36 34
75+ 873 1 164 856 590 1 987 313 762 112 309 3 483
16 19 19 24 22 27 22 3 26 19
Sex
Male 1 616 1 900 2 312 1 445 <0.001 3 175 620 2 254 519 705 7 273 <0.001
30 31 52 59 35 54 66 14 59 39
Female 3 859 4 311 2 163 984 5 896 526 1 158 3 246 491 11 317
70 69 48 41 65 46 34 86 41 61
Deprivation score
Quintile 1 (least de-
prived)
1 311 1 430 1 026 526 <0.001 2 060 238 808 916 271 4 293 0.079
24 23 23 22 23 21 24 24 23 23
Quintile 2 1 323 1 525 992 559 2 149 272 817 896 265 4 399
24 25 22 23 24 24 24 24 22 24
Quintile 3 1 139 1 399 957 549 1 996 239 746 795 268 4 044
21 23 21 23 22 21 22 21 22 22
Quintile 4 991 1 090 826 420 1 611 217 595 697 207 3 327
18 18 18 17 18 19 17 19 17 18
Quintile 5 (most de-
prived)
711 767 674 375 1 255 180 446 461 185 2 527
13 12 15 15 14 16 13 12 15 14
Cancer site
Breast 3 367 3 556 988 216 <0.001 4 549 85 415 2 978 100 8 127 <0.001
62 57 22 9 50 7 12 79 8 44
Prostate 940 880 779 417 1 355 102 1 317 0 242 3 016
17 14 17 17 15 9 39 0 20 16
Colon 352 1 046 1 160 633 1 112 562 697 500 320 3 191
6 17 26 26 12 49 20 13 27 17
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Lung 482 371 719 856 1 174 306 560 0 388 2 428
9 6 16 35 13 27 16 0 32 13
Rectal 334 358 829 307 881 91 423 287 146 1 828
6 6 19 13 10 8 12 8 12 10
Total 5 475 6 211 4 475 2 429 9 071 1 146 3 412 3 765 1 196 18 590
100 100 100 100 100 100 100 100 100 100
ap-values from Chi-square tests of associations.
Note: values displayed as frequency (top of cell) and percentage (bottom of cell).
Appendix 3 Adjusted odds ratios of reporting a negative experience of overall cancer care, N= 18 590
Variable Odds ratioa 95% confidence interval pb
Age group
<55 1.59 1.37 – 1.84 <0.001
55-64 1.16 1.01 – 1.32
65-74 1
75+ 1.16 1.00 – 1.34
Sex
Male 1 <0.001
Female 1.51 1.30 – 1.76
Deprivation score
Quintile 1 (least deprived) 1 <0.001
Quintile 2 1.12 0.96 – 1.30
Quintile 3 1.18 1.02 – 1.38
Quintile 4 1.08 0.92 – 1.26
Quintile 5 (most deprived) 1.49 1.26 – 1.75
Cancer site
Breast 0.62 0.39 – 0.99 0.003
Prostate 1.12 0.68 – 1.85
Colon 1.14 0.64 – 2.03
Lung 0.74 0.42 – 1.29
Rectal 1
Tumour stage at diagnosis
I 1 0.717
II 1.26 0.76 – 2.08
III 1.08 0.69 – 1.70
IV 0.96 0.56 – 1.66
Diagnostic route
Two-week-wait 1 0.034
Emergency presentation 1.82 1.01 – 3.27
Elective referral 1.13 0.78 – 1.63
Screening detection 0.54 0.30 – 0.95
Other routes 0.93 0.51 – 1.69
Cancer site & stage interaction
Breast#stage I 1 0.117
Breast#stage II 0.73 0.43 – 1.26
Breast#stage III 1.14 0.69 – 1.91
Breast#stage IV 1.88 0.95 – 3.73
Prostate#stage I 1
Prostate#stage II 0.79 0.44 – 1.42
Prostate#stage III 0.97 0.56 – 1.67
Prostate#stage IV 1.61 0.84 – 3.07
Colon#stage I 1
Colon#stage II 0.48 0.25 – 0.93
Colon#stage III 0.74 0.40 – 1.35
Colon#stage IV 1.19 0.60 – 2.39
Lung#stage I 1
Lung#stage II 0.93 0.47 – 1.84
Lung#stage III 1.16 0.64 – 2.11
Lung#stage IV 1.35 0.70 – 2.63
Cancer site & route interaction
Breast#Two-week-wait 1 0.628
Breast#Emergency presentation 0.73 0.31 – 1.75
Breast#Elective referral 0.86 0.52 – 1.43
Breast#Screening detection 1.71 0.94 – 3.10
Breast#Other routes 0.79 0.30 – 2.11
Prostate#Two-week-wait 1
Prostate#Emergency presentation 1.16 0.52 – 2.55
Prostate#Elective referral 1.28 0.82 – 1.99
Prostate#Screening detection 1
Prostate#Other routes 1.30 0.62 – 2.73
Colon#Two-week-wait
Colon#Emergency presentation 0.70 0.36 – 1.37
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Colon#Elective referral 0.97 0.60 – 1.58
Colon#Screening detection 1.40 0.69 – 2.83
Colon#Other routes 1.00 0.48 – 2.10
Lung#Two-week-wait 1
Lung#Emergency presentation 0.85 0.42 – 1.71
Lung#Elective referral 1.29 0.79 – 2.10
Lung#Screening detection 1
Lung#Other routes 1.07 0.52 – 2.20
aOdds ratios from multivariable logistic regression model, conditional on tumour stage, diagnostic route, patient characteristic and cancer site variables, as well as pairwise interactions
between cancer site and tumour stage or diagnostic route.
bp-values from joint Wald tests.
#, interaction.
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